The BCG Vaccine is a vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.
The tuberculosis vaccine (or BCG vaccine) does not protect elderly with co-morbidities against disease symptoms caused by a coronavirus infection.
Announcing a new article publication for Zoonoses journal. This study was aimed at screening differentially expressed genes (DEGs) and exploring the potential immune mechanism induced by the Bacillus Calmette-Guerin (BCG) vaccine in a humanized mouse model.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, primarily causes mild to moderate upper-respiratory tract illness. However, some individuals with COVID-19 develop severe infections and require hospital admission.
In a new study, researchers assessed the ecological association suggesting the efficacy of bacillus Calmette-Guerin (BCG) vaccination against COVID-19.
A modified tuberculosis (TB) vaccine developed at Texas Biomed could help treat a form of bladder cancer, called non-muscle invasive bladder cancer, without strong side effects.
A recent article demonstrated that BCG vaccinations might offer a platform for protection against emerging SARS-CoV-2 variants and other pathogenic infections in type 1 diabetics.
The immune boosting benefits of a tuberculosis vaccine can be seen in infants more than one year after vaccination, according to a new study.
In this interview, we speak to Charles Wells from Gates MRI about their current research into tuberculosis (TB) as well as the recent updated guidelines for TB care.
The University of Oxford has begun recruiting for a Phase I trial with a tuberculosis vaccine in human volunteers at Oxford to develop a new way to test the efficacy of future TB vaccines - with the first volunteers being challenged today (Wednesday).
The century-old Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is one of the world's oldest and most widely used vaccines, used to immunize 100 million newborns every year. Given in countries with endemic TB, it has surprisingly been found to protect newborns and young infants against multiple bacterial and viral infections unrelated to TB. There's even some evidence that it can reduce severity of COVID-19.
In a recent study posted to the bioRxiv* preprint server, the researchers investigated the impact of Bacillus Calmette-Guérin (BCG) vaccine-induced antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein.
Researchers tested the effectiveness of the BCG vaccine in SARS-CoV-2-infected Syrian hamsters.
We speak to Dr. Alemnew Dagnew from the Bill & Melinda Gates Medical Research Institute, about their tuberculosis vaccine study and the future of tuberculosis.
Briefly blocking a key molecule when administering the only approved vaccine for tuberculosis vastly improves long-term protection against the devastating disease in mice, researchers from Texas Biomedical Research Institute report this week in the Journal of Immunology.
Researchers at Massachusetts General Hospital, in partnership with NYU Langone Health, have launched a multi-center clinical trial to investigate a new treatment for pediatric type 1 diabetes even in subjects with established disease.
Researchers investigated the effectiveness of the BCG vaccines against SARS-CoV-2 infections using three animal models.
A new paper finds that the influenza vaccine may influence both the response to and incidence of infection by the SARS-CoV-2.
A recent US study, currently available on bioRxiv* preprint server, implies that vaccination with bacille Calmette-Guérin (BCG) can limit the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by targeting innate immune pathways and could thus be used as a platform for pinpointing early immunologic events affecting the outcome of coronavirus disease (COVID-19).
A new study estimates vaccine effectiveness against COVID-19 mortality in England using the RDD approach.
At the recent 2021 Annual Scientific Sessions of the American Diabetes Association, researchers from Massachusetts General Hospital (MGH) presented positive updates on their trials of the bacillus Calmette-Guérin (BCG) vaccine to safely and significantly lower blood sugars.